Supplementary Figure 2.pptx (164.87 kB)
Supplementary Figure 2: Introducing dendritic cell antibody internalization as an immunogenicity risk assessment tool
figure
posted on 2022-05-20, 14:13 authored by Rachel Melendez, Benjamin Ordonia, Joyce Guerrero, Azadeh Hassanzadeh, Peter Tran, Justin Low, Manda Wong, Jochen Brumm, Shan Chung, Lynn Kamen
Supplemental Figure 2. FcgR Binding. Bococizumab and trastuzuamb were measured for binding to the low affinity FcgRIIA receptor, as compared to linking with the FRET probe. To confirm that the binding is Fc-related, the biotherapeutic/FRET pairs were incubated with anti-CD32 (Fc block).
